{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:35Z","timestamp":1791932615137,"version":"4.3.4"},"reference-count":66,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed\/refractory (R\/R) disease after treatment with a Bruton\u2019s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whether brexu-cel was cost-effective for the treatment of R\/R MCL. We developed a partitioned survival mixture cure approach to model the costs and outcomes over a lifetime horizon. The clinical data were derived from the ZUMA-2 clinical trial. The costs were estimated from the publicly available Canadian databases, published oncology literature, and pan-Canadian Oncology Drug Review economic guidance reports. The health state utilities were sourced from the ibrutinib submission to the National Institute for Health and Care Excellence for R\/R MCL and supplemented with values from the published oncology literature. In the base case over a lifetime horizon, brexu-cel generated an incremental 9.56 life-years and an additional 7.03 quality-adjusted life-years compared to BSC, while associated with CAD 621,933 in additional costs. The resultant incremental cost-utility ratio was CAD 88,503 per QALY gained compared with BSC. Based on this analysis, we found brexu-cel to be a cost-effective use of healthcare resources relative to BSC for treatment of adult patients with R\/R MCL previously treated with a BTKi in Canada, though additional research is needed to confirm these results using longer follow-up data.<\/jats:p>","DOI":"10.3390\/curroncol29030164","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:26:22Z","timestamp":1647811582000},"page":"2021-2045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed\/Refractory Mantle Cell Lymphoma following Treatment with a Bruton\u2019s Tyrosine Kinase Inhibitor in Canada"],"prefix":"10.3390","volume":"29","author":[{"given":"Graeme","family":"Ball","sequence":"first","affiliation":[{"name":"Gilead Sciences Canada, Inc., Mississauga, ON L5N 2W3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lemieux","sequence":"additional","affiliation":[{"name":"Medicine Department, Laval University, Qu\u00e9bec, QC G1V 0A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[{"name":"PIVINA Consulting Inc., Mississauga, ON L4W 5B2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Seftel","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V1Y 1T3, Canada"},{"name":"Canadian Blood Services, Vancouver, BC V6T 1V6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Klener, P. (2019). Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184417"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Habermann","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_4","first-page":"e015106","article-title":"Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: A population-based study using cancer registry data","volume":"7","author":"Ye","year":"2017","journal-title":"Br. Med. J. Open"},{"key":"ref_5","unstructured":"Pan-Canadian Oncology Drug Review (2016). Pan-Canadian Oncology Drug Review. Final Economic Guidance Report-Ibrutinib for Mantle Cell Lymphoma, Pan-Canadian Oncology Drug Review."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: Sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3324\/haematol.2014.107300","article-title":"Trends in incidence, treatment and survival of aggressive B-cell lymphoma in The Netherlands 1989\u20132010","volume":"100","author":"Issa","year":"2015","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-Term Outcomes and Mutation Profiling of Patients with Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational Study of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed\/Progressed After or Were Refractory\/Intolerant to Ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"U.S. Food & Drug Administration (2021, July 23). Supplement Approval, Available online: https:\/\/www.fda.gov\/media\/146253\/download."},{"key":"ref_18","unstructured":"(2021, August 16). Health Canada Notice of Compliance (NOC) Online Query. Available online: https:\/\/health-products.canada.ca\/noc-ac\/info.do?lang=en&no=26027."},{"key":"ref_19","unstructured":"Canadian Agency for Drugs and Technologies in Health (2021, April 22). Brexucabtagene Autoleucel. Available online: https:\/\/www.cadth.ca\/brexucabtagene-autoleucel."},{"key":"ref_20","unstructured":"(2021, August 23). Final Appraisal Document Autologous Anti-CD19-Transduced CD3+ Cells for Treating Relapsed or Refractory Mantle Cell Lymphoma. Available online: https:\/\/www.nice.org.uk\/guidance\/ta677\/documents\/final-appraisal-determination-document."},{"key":"ref_21","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2021). Reimbursement Recommendation: Brexucabtagene Autoleucel (Tecartus), Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1536867X0700700304","article-title":"Modeling of the cure fraction in survival studies","volume":"7","author":"Lambert","year":"2007","journal-title":"Stata J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J. Med. Econ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/13696998.2021.1901721","article-title":"Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States","volume":"24","author":"Liu","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jval.2021.04.200","article-title":"PCN108 Cost-Effectiveness of Axicabtagene Ciloleucel (AXI-CEL) and Tisagenlecleucel (TISA-CEL) in Adult Patients with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL) in Canada","volume":"24","author":"Ball","year":"2021","journal-title":"Value Health"},{"key":"ref_27","unstructured":"CADTH (2018). Guidelines for the Economic Evaluation of Health Technologies: Canada, CADTH. [4th ed.]."},{"key":"ref_28","unstructured":"(2021, August 12). Guidelines for the Economic Evaluation of Health Technologies: Canada. Available online: https:\/\/www.cadth.ca\/about-cadth\/how-we-do-it\/methods-and-guidelines\/guidelines-for-the-economic-evaluation-of-health-technologies-canada."},{"key":"ref_29","unstructured":"(2018, January 02). NICE DSU Technical Support Document 19: Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. Available online: http:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wp-content\/uploads\/sites\/7\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: An exploration of methods for review, economic evaluation and appraisal","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol. Assess."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2019-125792","article-title":"A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"ref_35","unstructured":"Statistics Canada (2020). Life Tables, Canada, Provinces and Territories 1980\/1982 to 2016\/2018."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_37","unstructured":"(2017, December 19). NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations alongside Clinical Trials-Extrapolation with Patient-Level Data. Available online: http:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wp-content\/uploads\/sites\/7\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf."},{"key":"ref_38","unstructured":"Precision HEOR KP (2020). Meta-Analysis and Indirect Comparison of Interventions for Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Bruton Tyrosine Kinase Inhibitors, Precision HEOR."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Guyot, P., Ades, A.E., Ouwens, M.J., and Welton, N.J. (2012). Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-9"},{"key":"ref_40","unstructured":"Bank of Canada (2021, December 10). @bankofcanada. Available online: https:\/\/www.bankofcanada.ca\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/082585971102700203","article-title":"Resource use and costs of end-of-Life\/palliative care: Ontario adult cancer patients dying during 2002 and 2003","volume":"27","author":"Walker","year":"2011","journal-title":"J. Palliat. Care"},{"key":"ref_42","unstructured":"Kite Pharma Inc. (2019). Clinical Study Report, Primary Analysis: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed\/Refractory Mantle Cell Lymphoma (ZUMA-2), Kite Pharma Inc."},{"key":"ref_43","unstructured":"Ministry of Health and Long Term Care (2020). Schedule of Benefits: Physician Services under the Health Insurance Act."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbmt.2012.12.006","article-title":"Safety and Cost-Effectiveness of Outpatient Autologous Stem Cell Transplantation in Patients with Multiple Myeloma","volume":"19","author":"Holbro","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_45","unstructured":"Canadian Institute for Health Information (2020). Patient Cost Estimator, Canadian Institute for Health Information."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0885066619899653","article-title":"Costs and Outcomes of Patients Admitted to the Intensive Care Unit with Cancer","volume":"36","author":"Zheng","year":"2020","journal-title":"J. Intensive Care Med."},{"key":"ref_47","unstructured":"Ministry of Health and Long Term Care (2019). Exceptional Access Program."},{"key":"ref_48","unstructured":"Pan-Canadian Oncology Drug Review (2013). Pan-Canadian Oncology Drug Review. Final Economic Guidance Report-Bendamustine, Pan-Canadian Oncology Drug Review."},{"key":"ref_49","unstructured":"(2020, May 21). Final Economic Guidance Report Daratumumab (Darzalex) + VMP for Multiple Myeloma. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_daratumumab_darzalex_mm_fn_rec.pdf."},{"key":"ref_50","unstructured":"Pan-Canadian Oncology Drug Review (2018). Pan-Canadian Oncology Drug Review. Final Economic Guidance Report Pertuzumab-Trastuzumab for Early Breast Cancer, Pan-Canadian Oncology Drug Review."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/2040620716648566","article-title":"Bortezomib for the treatment of mantle cell lymphoma: An update","volume":"7","author":"Hambley","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"ref_52","unstructured":"(2021, September 14). Anthracyclines, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538187\/."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/2040620714532124","article-title":"Lenalidomide in relapsed or refractory mantle cell lymphoma: Overview and perspective","volume":"5","author":"Desai","year":"2014","journal-title":"Ther. Adv. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood.V118.21.2677.2677","article-title":"Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen in Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant","volume":"118","author":"Visco","year":"2011","journal-title":"Blood"},{"key":"ref_55","unstructured":"Ministry of Health and Long Term Care (2020). Schedule of Benefits for Laboratory Services."},{"key":"ref_56","unstructured":"(2019, August 15). Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma. Technology Appraisal Guidance [TA502]-Committee Papers. Available online: https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/committee-papers."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: Moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1447828","DOI":"10.1080\/16549716.2018.1447828","article-title":"On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: A systematic review","volume":"11","author":"Cameron","year":"2018","journal-title":"Glob. Health Action"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/bloodadvances.2020001646","article-title":"The conditional survival analysis of relapsed DLBCL after autologous transplant: A subgroup analysis of LY.12 and CORAL","volume":"4","author":"Assouline","year":"2020","journal-title":"Blood Adv."},{"key":"ref_60","unstructured":"(INESSS) Indeesess (2021, November 27). Avis au Ministre-TECARTUS pour le Traitement du Lymphome \u00e0 Cellules du Manteau. Available online: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Juillet_2021\/Tecartus__06.pdf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13696998.2021.1894158","article-title":"Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States","volume":"24","author":"Simons","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies","volume":"4","author":"Tang","year":"2021","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/bjh.17197","article-title":"Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy","volume":"192","author":"Jain","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0272989X18820535","article-title":"Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models","volume":"39","author":"Bansal","year":"2019","journal-title":"Med. Decis. Mak."},{"key":"ref_66","unstructured":"(2021, November 27). Ontario Drug Benefit Formulary\/Comparative Drug Index 2021, Available online: https:\/\/www.formulary.health.gov.on.ca\/formulary\/."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:38:03Z","timestamp":1760135883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":66,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["curroncol29030164"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29030164","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]}}}